Short-term Therapy with R568 Ameliorated Secondary Hyperparathyroidism but Does Not Prevent Aortic Valve Calcification in Uremic Rats

Overview

Journal Front Nephrol

Specialty Nephrology

Date 2024 Aug 21

PMID 39165274

Authors

Asmahan Abu-Snieneh

Irina Gurt

Suzan Abedat

Chaim Lotan

Michael Glikson

Mony Shuvy

Affiliations

Soon will be listed here.

Abstract

Introduction: Renal failure associated aortic valve calcification (AVC) is the result of hyperphosphatemia and hyperparathyroidism. Calcimimetics is an effective tool for management of secondary hyperparathyroidism. Our goal was to evaluate the effect of the medical intervention with calcimimetic R568 on the AVC process.

Methods And Results: The experimental design consisted of administering a uremia-inducing phosphate-enriched diet to rats for six weeks. Rats received a daily R568 injection at different times. Biochemical analysis demonstrated increased urea (34.72 ± 3.57 . 5.18 ± 0.15 mmol/L, <0.05) and creatinine (293.93 ± 79.6 . 12.82 ± 1.56 µmol/L, <0.05). R568 treatment markedly reduced parathyroid hormone (PTH) levels in both treated groups (192.63 ± 26.85, 301.23 ± 101.79 . 3570 ± 986.63 pg/mL, <0.05), with no impact on serum calcium and phosphate. von Kossa staining showed increase in AVC in uremic rats compared to control (1409 ± 159.5 . 27.33 ± 25.83, <0.05). AVC was not affected by R568 in both groups (3343 ± 2462, 1593 ± 792 . 1409 ± 159.5, NS). Similarly, the inflammatory marker CD68 was elevated in uremic rats (15592 ± 3792 . 181.8 ± 15.29, <0.01), and was not influenced by R568 treatment (8453 ± 818.5, 9318 ± 2232 . 15592 ± 3792, NS). Runt-related transcription factor 2 (Runx2), the regulator of osteoblast differentiation, was upregulated in uremic rats (23186 ± 9226 . 3184 ± 2495), that accompanied by elevated levels of Osteopontin (158395 ± 45911 . 237.7 ± 81.5, <0.05) and Osteocalcin (22203 ± 8525 . 489.7 ± 200.6, <0.05). R568 had no impact on osteoblastic markers (Runx2: 21743 ± 3193, 23004 ± 10871 . 23186 ± 9226, NS; osteopontin: 57680 ± 19522, 137116 ± 60103 . 158395 ± 45911, NS; osteocalcin: 10496 ± 5429, 8522 ± 5031 . 22203 ± 8525, NS).

Conclusion: In an adenine-induced uremic rat model, we showed that short-term R568 therapy had no effect on AVC. Treatment with R568 decreased PTH levels but had no effect on high phosphate levels. Regression of AVC necessitates not only a decrease in PTH levels, but also a decline in phosphate levels. To achieve improved outcomes, it is advisable to consider administering a combination of R568 with other medications, such as calcium supplements or phosphate binders. Additional studies are required for further evaluation of the potential treatment of chronic kidney disease (CKD)-associated AVC.

References

Di Lullo L, Gorini A, Bellasi A, Morrone L, Rivera R, Russo L . Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease. Clin Kidney J. 2015; 8(6):732-6. PMC: 4655786. DOI: 10.1093/ckj/sfv073. View

Kume T, Kawamoto T, Akasaka T, Watanabe N, Toyota E, Neishi Y . Rate of progression of valvular aortic stenosis in patients undergoing dialysis. J Am Soc Echocardiogr. 2006; 19(7):914-8. DOI: 10.1016/j.echo.2006.01.026. View

Block G, Zaun D, Smits G, Persky M, Brillhart S, Nieman K . Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010; 78(6):578-89. DOI: 10.1038/ki.2010.167. View

Ivanovski O, Nikolov I, Joki N, Caudrillier A, Phan O, Mentaverri R . The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis. 2009; 205(1):55-62. DOI: 10.1016/j.atherosclerosis.2008.10.043. View

Levi R, Ben-Dov I, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Many T . Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol. 2005; 17(1):107-12. DOI: 10.1681/ASN.2005070679. View

Iwamoto N, Sato N, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S . Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients. Clin Exp Nephrol. 2015; 20(5):808-814. DOI: 10.1007/s10157-015-1208-x. View

Linefsky J, OBrien K, Sachs M, Katz R, Eng J, Michos E . Serum phosphate is associated with aortic valve calcification in the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2014; 233(2):331-337. PMC: 3992246. DOI: 10.1016/j.atherosclerosis.2013.12.051. View

Koleganova N, Piecha G, Ritz E, Peter Schmitt C, Gross M . A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int. 2008; 75(1):60-71. DOI: 10.1038/ki.2008.490. View

Rajamannan N, Nealis T, Subramaniam M, Pandya S, Stock S, Ignatiev C . Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005; 111(24):3296-301. PMC: 3951870. DOI: 10.1161/CIRCULATIONAHA.104.473165. View

10.

Malluche H, Blomquist G, Monier-Faugere M, Cantor T, Davenport D . High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. J Am Soc Nephrol. 2015; 26(10):2534-44. PMC: 4587691. DOI: 10.1681/ASN.2014070686. View

11.

Iwata S, Walker M, Di Tullio M, Hyodo E, Jin Z, Liu R . Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2011; 97(1):132-7. PMC: 3251929. DOI: 10.1210/jc.2011-2107. View

12.

Cannata-Andia J, Carrera F . The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. NDT Plus. 2015; 1(Suppl 1):i2-i6. PMC: 4421153. DOI: 10.1093/ndtplus/sfm037. View

13.

Wu M, Tang R, Liu H, Pan M, Liu B . Cinacalcet ameliorates aortic calcification in uremic rats via suppression of endothelial-to-mesenchymal transition. Acta Pharmacol Sin. 2016; 37(11):1423-1431. PMC: 5099416. DOI: 10.1038/aps.2016.83. View

14.

Chen Y, Zhao X, Wu H . Arterial Stiffness: A Focus on Vascular Calcification and Its Link to Bone Mineralization. Arterioscler Thromb Vasc Biol. 2020; 40(5):1078-1093. PMC: 7199843. DOI: 10.1161/ATVBAHA.120.313131. View

15.

Rodriguez M, Aguilera-Tejero E, Mendoza F, Guerrero F, Lopez I . Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. Kidney Int Suppl. 2008; (111):S50-4. DOI: 10.1038/ki.2008.546. View

16.

Hannan F, Kallay E, Chang W, Brandi M, Thakker R . The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 2018; 15(1):33-51. PMC: 6535143. DOI: 10.1038/s41574-018-0115-0. View

17.

Raggi P, Chertow G, Urena Torres P, Csiky B, Naso A, Nossuli K . The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2010; 26(4):1327-39. DOI: 10.1093/ndt/gfq725. View

18.

Jung S, Querfeld U, Muller D, Rudolph B, Peters H, Kramer S . Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. J Hypertens. 2012; 30(11):2182-91. DOI: 10.1097/HJH.0b013e328357c049. View

19.

Schlieper G, Floege J . Calcimimetics in CKD-results from recent clinical studies. Pediatr Nephrol. 2008; 23(10):1721-8. PMC: 6901399. DOI: 10.1007/s00467-008-0900-4. View

20.

Chen H, Engert J, Thanassoulis G . Risk factors for valvular calcification. Curr Opin Endocrinol Diabetes Obes. 2019; 26(2):96-102. PMC: 6873465. DOI: 10.1097/MED.0000000000000471. View